Companies / Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc.

Nasdaq: ATOSCIK 1488039SEATTLE, WAatossatherapeutics.com

Financials · FY2015

Revenue$1.8K
Net income$-34.77M
Total debt
Cash$26.09M
Diluted EPS$-4.04
Shares outstanding10.0M

Ownership

10.0M shares outstanding · as of Jul 31, 2026
1.6%Insiders
Ownership
Insiders1.61%161,038
Institutions5.07%505,866
Public float93.32%9,312,394

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 3

View all →
Insider% of sharesShares
Quay Steven CCEOPresident & CEO · Director
0.88%88,038
Daniel Mark JamesChief Financial Officer
0.63%63,000
0.10%10,000

Institutional holders 10

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
Renaissance Technologies LLC
13F manager
NewCommon Stock$573.4K+109K
109,007
1.09% of shares
low
Q1 2026
as of
Geode Capital Management, LLC
13F manager
NewCommon Stock$510.7K+97K
97,061
0.97% of shares
low
Q1 2026
as of
Millennium Management LLC
13F manager
NewCommon Stock$351.0K+67K
66,739
0.67% of shares
low
Q2 2026
as of
BlackRock, Inc.
13F manager
NewCommon Stock$317.2K+164K
164,358
1.65% of shares
low
Q2 2026
as of
State Street Corporation
13F manager
NewCommon Stock$76.7K+40K
39,761
0.40% of shares
low
Q1 2026
as of
Marshall Wace, LLP
13F manager
ExitCommon Stock$-16.6K-28K
-100.00%
0
low
Q1 2026
as of
Royal Bank of Canada
13F manager
NewCommon Stock$3.0K+644
644
<0.01% of shares
low
Q1 2026
as of
BNP Paribas Financial Markets
13F manager
NewCommon Stock$515+98
98
<0.01% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
ATOSCommon StockEquity04962H704BBG002NCD8C8